Jakarta, CNBC Indonesia – The Oxford Astrazeneca coronavirus vaccine, developed by British pharmaceutical giant AstraZeneca and the University of Oxford, will undergo final trials.
Launching CNBC, there are several independent reports published in medical journals about the provisional results of the vaccine. The study, published Tuesday (8/12) in The Lancet, reaffirms the findings of trials for the vaccine that showed an average 70% effectiveness in protecting against the coronavirus.
This also confirmed the findings for the dosing regimen used in the trial, 62% efficacy for the two full doses and 90% efficacy for the half-full dose regimen.
Oxford vaccination professor who leads the vaccine project Sarah Gilbert said it was a very good day for the UK. And perhaps the best day to experience in 2020.
“Not only today are we seeing the first launch of the NHS vaccination against Covid-19, (but) on our part, we can present you with our data in a full peer-reviewed publication with all the information people have asked about us,” said Sarah Gilbert.
“And we now see that the vaccine is safe, very effective and we also know that it can be produced in large quantities and at a low price,” he said.
The vaccine is expected to receive regulatory approval in the coming weeks.
Experimental Age Group
Data for the trial that ran through November 4 were analyzed from 23,745 adult participants in the UK, Brazil and South Africa. About 82% of the trial participants were 18 to 55 years old.
People aged 56 and over were recruited to take part later. The University of Oxford said the effectiveness of the vaccine in this older age group could not yet be assessed but would be analyzed in the future as more data were obtained.
The age group tested in the trial has come to the attention of the head of Operations Warp Speed of the White House, Moncef Slaoui, and others in the US, who have shown that 90% effectiveness rates are shown only for lower-risk groups, which number 2,741 people under the age of 55 year.
The Lancet study said the vaccine was shown to be safe, with only three of the 23,745 participants experiencing serious side effects. This may be related to vaccine administration for a median of 3.4 months.
All three have recovered or are in the process of recovering and continue to be part of the pilot.
(hps / hps)
– .
